Dr. Erez Nevo is the CEO of Robin Medical, a small company operating in Baltimore, MD, and a Visiting Scientist in the Department of Medicine, The Johns Hopkins University School of Medicine.
Targeted therapy aims to individualize therapy according to the specific features of each patient’s disease. It is largely based on biomarkers – altered proteins and genetic molecules that are related to the disease in the individual patient. As many of these biomarkers are sensitive to physical and chemical factors, the requirements imposed on the acquisition and processing of tissue samples have become more stringent.
Robin Medical main product is the EndoScout tracking system for MRI-guided surgical interventions. Based on the experience gained in interventional devices we won NIH SBIR contracts and grants, totaling $2.5 Million, to develop new technologies for better preservation of biopsy tissue. This led to the development of the MCBD (multi-core biopsy device), an optimized biopsy device with unique advantages:
- The new device enables rapid, consecutive acquisition and storage of multiple biopsy samples without the need to remove and reinsert the needle to the target.
- All samples fixation is done within the biopsy device – either by freezing or by formalin fixation; there is no time delay to fixation which ensures preservation of labile biomarkers.
- The biopsy procedure is standardized and highly repeatable, with the same very short time delay between tissue cut and fixation for all samples and in all subjects.
- The new device provides innovative dual-mode preservation that fixes part of the sample by formalin for histology and part of the sample by freezing for biomarker analysis.